BPC-157 (10 mg Vial) Dosage Protocol
BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a protective sequence in human gastric juice. Preclinical research demonstrates wide-ranging effects on tendon, ligament, gut, and vascular healing. This page covers the 10 mg vial.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
Community-reported use: The table uses a once-daily subcutaneous frequency to keep the vial-use and supply calculations reproducible. It is not a clinically validated human BPC-157 dosing schedule. Animal doses cannot be converted directly into a human injection protocol, and published human evidence does not validate these 200–600 mcg rows.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Research reference only: The chart combines community-reported amounts with transparent concentration and syringe-conversion math for a 10 mg vial. It is not a validated human treatment schedule or medical advice.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (BPC-157, 10 mg each) | 8 weeks: approximately 3 vials required (25.2 mg used) 12 weeks: approximately 5 vials required (42 mg used) 16 weeks: approximately 6 vials required (58.8 mg used) |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each) 12 weeks (5 vials): 15 mL — 2 bottles required (10 mL each) 16 weeks (6 vials): 18 mL — 2 bottles required (10 mL each) |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs — 2 boxes required (100 swabs each) 12 weeks: 168 swabs — 2 boxes required (100 swabs each) 16 weeks: 224 swabs — 3 boxes required (100 swabs each) |
Protocol Overview
There is no established long-term safety data, so cycling is the conservative default. Local vs systemic: Subcutaneous injection close to the affected area is favored when feasible. For systemic protocols (gut, vascular), abdomen or thigh injection works fine.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
BPC-157 is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body-protection compound found in gastric juice. It survives gastric acid that would destroy most peptides.
Animal models show: VEGFR2 upregulation accelerating angiogenesis at injury sites; modulation of nitric-oxide signaling; promotion of fibroblast migration and tendon-cell outgrowth; anti-inflammatory effects via downregulation of pro-inflammatory cytokines. The compound also stabilizes the gut-brain axis through serotonergic and dopaminergic modulation.
Potential Benefits & Side Effects
Potential Benefits
- Accelerated tendon and ligament healing in rodent models.
- Gastrointestinal protection: ulcer healing, IBD model improvements.
- Neuroprotection in models of TBI, stroke, and chemical neurotoxicity.
- Reduced muscle damage and faster recovery after eccentric exercise.
- Excellent safety profile in animal toxicology — no LD50 reached.
Side Effect Profile
- Generally well-tolerated; no major adverse events in published case series.
- Mild injection-site irritation possible.
- Rare reports of transient mild fatigue or nausea early.
- Theoretical angiogenesis concerns with occult malignancy.
- Long-term human safety data is limited.
Lifestyle Factors
- Inject as close to the affected area as practical when feasible.
- Maintain protein intake (1.2–1.6 g/kg/day) during active healing.
- Avoid NSAIDs during early-phase tendon/ligament healing — they may blunt repair.
- Vitamin C (500–1000 mg/day) supports collagen synthesis.
- Sleep 7–9 hours/night — most tissue repair occurs in deep sleep.
Injection Technique
- Subcutaneous most common; some literature uses intramuscular near the injury.
- Rotate injection sites if dosing twice daily.
- 90° angle with short (4–8 mm) insulin needle.
- Bring solution to room temperature before injecting.
- Hold 5 seconds after full plunger depression.